Syndax Pharmaceuticals Inc. Files DEF 14A Proxy Statement

Ticker: SNDX · Form: DEF 14A · Filed: Apr 2, 2024 · CIK: 1395937

Syndax Pharmaceuticals Inc DEF 14A Filing Summary
FieldDetail
CompanySyndax Pharmaceuticals Inc (SNDX)
Form TypeDEF 14A
Filed DateApr 2, 2024
Risk Levellow
Pages16
Reading Time20 min
Sentimentneutral

Sentiment: neutral

Topics: Syndax Pharmaceuticals, SNDX, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Syndax Pharmaceuticals Inc. has filed its DEF 14A proxy statement detailing executive compensation adjustments for equity awards.</b>

AI Summary

Syndax Pharmaceuticals Inc (SNDX) filed a Proxy Statement (DEF 14A) with the SEC on April 2, 2024. Syndax Pharmaceuticals Inc. filed a DEF 14A proxy statement on April 2, 2024. The filing covers the period ending March 27, 2024. The company's principal executive offices are located at 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451. The filing includes details on executive compensation adjustments related to equity awards for the fiscal years 2020-2023. Specific adjustments mentioned include changes in fair value of unvested equity awards and vesting date fair values.

Why It Matters

For investors and stakeholders tracking Syndax Pharmaceuticals Inc, this filing contains several important signals. This filing provides transparency into how executive compensation, particularly equity awards, is valued and adjusted over time, which is crucial for shareholder understanding and governance. Shareholders can review the detailed breakdown of compensation adjustments to assess the alignment of executive pay with company performance and shareholder interests.

Risk Assessment

Risk Level: low — Syndax Pharmaceuticals Inc shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial results or significant operational updates, indicating a low level of immediate risk.

Analyst Insight

Review the executive compensation details within the proxy statement to understand how equity awards are valued and adjusted, and how this impacts reported compensation figures.

Key Numbers

  • 2024-04-02 — Filing Date (Date the DEF 14A was filed)
  • 2024-03-27 — Period of Report (The reporting period for the DEF 14A)
  • 2023-12-31 — Fiscal Year End (Company's fiscal year end)
  • 2020-2023 — Compensation Adjustment Years (Years for which equity award compensation adjustments are detailed)

Key Players & Entities

  • Syndax Pharmaceuticals Inc. (company) — Filer of the DEF 14A
  • Michael A. Metzger (person) — Executive mentioned in compensation adjustments
  • Briggs W. Morrison (person) — Executive mentioned in compensation adjustments
  • 0000950170-24-040099 (other) — Accession Number for the filing
  • 2024-04-02 (date) — Filing date of the DEF 14A
  • 2024-03-27 (date) — Period of report for the DEF 14A
  • 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451 (address) — Business and mailing address of the company

FAQ

When did Syndax Pharmaceuticals Inc file this DEF 14A?

Syndax Pharmaceuticals Inc filed this Proxy Statement (DEF 14A) with the SEC on April 2, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Syndax Pharmaceuticals Inc (SNDX).

Where can I read the original DEF 14A filing from Syndax Pharmaceuticals Inc?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Syndax Pharmaceuticals Inc.

What are the key takeaways from Syndax Pharmaceuticals Inc's DEF 14A?

Syndax Pharmaceuticals Inc filed this DEF 14A on April 2, 2024. Key takeaways: Syndax Pharmaceuticals Inc. filed a DEF 14A proxy statement on April 2, 2024.. The filing covers the period ending March 27, 2024.. The company's principal executive offices are located at 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451..

Is Syndax Pharmaceuticals Inc a risky investment based on this filing?

Based on this DEF 14A, Syndax Pharmaceuticals Inc presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial results or significant operational updates, indicating a low level of immediate risk.

What should investors do after reading Syndax Pharmaceuticals Inc's DEF 14A?

Review the executive compensation details within the proxy statement to understand how equity awards are valued and adjusted, and how this impacts reported compensation figures. The overall sentiment from this filing is neutral.

How does Syndax Pharmaceuticals Inc compare to its industry peers?

Syndax Pharmaceuticals Inc. operates in the pharmaceutical preparations industry.

Are there regulatory concerns for Syndax Pharmaceuticals Inc?

The filing is a Schedule 14A (DEF 14A), a proxy statement required under the Securities Exchange Act of 1934.

Industry Context

Syndax Pharmaceuticals Inc. operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a Schedule 14A (DEF 14A), a proxy statement required under the Securities Exchange Act of 1934.

What Investors Should Do

  1. Analyze the specific adjustments to equity awards for named executive officers (NEOs) like Michael A. Metzger and Briggs W. Morrison.
  2. Compare the reported compensation figures with previous filings to identify trends in executive pay.
  3. Understand the methodology used for calculating the fair value of equity awards and any changes to vesting dates.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine proxy statement and does not represent a change from previous reporting periods in terms of filing type.

Filing Stats: 4,897 words · 20 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-02 16:00:29

Filing Documents

Executive Compensation Philosophy and Objectives

Executive Compensation Philosophy and Objectives 23 Pay Program Overview 23 CEO and Other NEO Pay Mix 24 Compensation Program Governance 24 Compensation Determination Process 25 Components of Our Executive Compensation Program 27 Additional Elements of Compensation 32 Report of Compensation Committee on Executive Compensation 32 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 33 Executive Officer Compensation 33 Outstanding Equity Awards at Fiscal Year-End 35 Option Exercises and Stock-Vested 36 Equity Plans 36 Employment Agreements with Named Executive Officers 37 Potential Payments Upon Termination or Change in Control 38 Pay Ratio Disclosure 40 Director Compensation 40 Limitation on Liability and Indemnification 41 Rule 10b5-1 Sales Plans 42 PAY VERSUS PERFORMANCE 43 Relationship Between PEO and Non-PEO NEO CAP, Company TSR and Peer Group TSR 45 Relationship Between PEO and Non-PEO NEO CAP and Net Income 45 Relationship Between PEO and Non-PEO NEO CAP and Stock Price 45 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 48 Policies and Procedures Regarding Transactions with Related Parties 48 Certain Related-Party Transactions 48

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 49

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 49 Securities Authorized for Issuance Under Equity Compensation Plans 51 i HOUSEHOLDING OF PROXY MATERIALS 52 OTHER MATTERS 52 ii SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM, MASSACHUSETTS 02451 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2024 AT 8:30 AM EDT GENERAL INFORMATION Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the " SEC "), we have elected to provide access to our proxy materials to our stockholders via the Internet. Accordingly, on or about April 2, 2024, we sent you a Notice Regarding Availability of Proxy Materials (" Notice of Internet Availability ") because the Board of Directors (the " Board ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. The Notice of 2024 Annual Meeting of Stockholders (" Notice of Annual Meeting "), this proxy statement and proxy card or, for shares held in "street name" (i.e., shares held for your account by a broker, bank or other agent), voting instruction form, and the Annual Report on Form 10-K for the year ending December 31, 2023 (collectively, the " Proxy Materials ") are available to stockholders on the Internet. Instructions on how to access the Proxy Materials over the Internet or to request a printed copy may be found in the Notice of Internet Availability. The Notice of Internet Availability will also provide instructions as to how stockholders may request that a printed set of the Proxy Materials, including a proxy card, be sent to them by mail. The Notice of Internet Availability will also provide voting instructions. As used in this proxy statement, "we," "us," "our" and the "Company" refer to Syndax Pharmaceuticals, Inc. The term "Annu

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.